Evidence map›Paper›PMID 28630439›Full record

ArticleLeukemia2017

Recurrent cyclin D2 mutations in myeloid neoplasms.

V Khanna, C A Eide, C E Tognon, J E Maxson, B Wilmot, D Bottomly, S McWeeney, D K Edwards V, B J Druker, J W Tyner

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Atypical CML: diagnosis and treatment.Hematology. American Society of Hematology. Education Program · 2023
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

V KhannaKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
C A EideKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
C E TognonKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
J E MaxsonKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
B WilmotKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
D BottomlyKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
S McWeeneyKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-8333-6607
D K Edwards VKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
B J DrukerKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
J W TynerKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Oregon Health & Science University · USHoward Hughes Medical Institute · US

Funding

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3M
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven CancerR01CA183974 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2014 to 2018
$1.6M
Pathogenic Mechanisms of CSF3R Mutations in LeukemiaR00CA190605 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MAXSON, JULIA E · 2016 to 2018
$733k
ROR1 as a Therapeutic Target in Acute Lymphoblastic LeukemiaR00CA151457 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2012 to 2014
$723k
NCI NIH HHS R00 CA151457NCI NIH HHS R00 CA190605NCI NIH HHS R01 CA183974NCI NIH HHS U01 CA217862
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAnimalsCyclin D2HumansMiceMyeloproliferative DisordersNIH 3T3 CellsCCND2 protein, humanCyclin D2

Identifiers

PMID28630439
PMCPMC5763909
OpenAlexW2683402812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.